1. Home
  2. MYGN vs AHH Comparison

MYGN vs AHH Comparison

Compare MYGN & AHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYGN
  • AHH
  • Stock Information
  • Founded
  • MYGN 1991
  • AHH 1979
  • Country
  • MYGN United States
  • AHH United States
  • Employees
  • MYGN N/A
  • AHH N/A
  • Industry
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • AHH Real Estate
  • Sector
  • MYGN Health Care
  • AHH Finance
  • Exchange
  • MYGN Nasdaq
  • AHH Nasdaq
  • Market Cap
  • MYGN 625.5M
  • AHH 543.5M
  • IPO Year
  • MYGN 1995
  • AHH 2013
  • Fundamental
  • Price
  • MYGN $6.65
  • AHH $6.21
  • Analyst Decision
  • MYGN Hold
  • AHH Buy
  • Analyst Count
  • MYGN 14
  • AHH 4
  • Target Price
  • MYGN $13.23
  • AHH $8.13
  • AVG Volume (30 Days)
  • MYGN 1.1M
  • AHH 797.7K
  • Earning Date
  • MYGN 11-03-2025
  • AHH 11-03-2025
  • Dividend Yield
  • MYGN N/A
  • AHH 13.12%
  • EPS Growth
  • MYGN N/A
  • AHH N/A
  • EPS
  • MYGN N/A
  • AHH 0.19
  • Revenue
  • MYGN $825,300,000.00
  • AHH $452,636,000.00
  • Revenue This Year
  • MYGN $0.06
  • AHH N/A
  • Revenue Next Year
  • MYGN $5.68
  • AHH $3.21
  • P/E Ratio
  • MYGN N/A
  • AHH $33.10
  • Revenue Growth
  • MYGN 0.21
  • AHH N/A
  • 52 Week Low
  • MYGN $3.76
  • AHH $6.10
  • 52 Week High
  • MYGN $16.83
  • AHH $11.24
  • Technical
  • Relative Strength Index (RSI)
  • MYGN 41.25
  • AHH 37.27
  • Support Level
  • MYGN $6.25
  • AHH $6.14
  • Resistance Level
  • MYGN $6.83
  • AHH $6.46
  • Average True Range (ATR)
  • MYGN 0.43
  • AHH 0.18
  • MACD
  • MYGN -0.09
  • AHH -0.01
  • Stochastic Oscillator
  • MYGN 23.90
  • AHH 13.68

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

About AHH Armada Hoffler Properties Inc.

Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States. It lease its properties under operating leases and recognize base rents. It also recognize revenue from tenant recoveries, through which tenants reimburses the company for expenses paid by them such as utilities, janitorial, repairs and maintenance. The company's operating segment includes office real estate, retail real estate, multifamily residential real estate, and general contracting, real estate financing and real estate services. It generates maximum revenue from the retail real estate segment.

Share on Social Networks: